In 2012, SS Jameson et al. published a study aiming to determine factors predictive of revision (replacement) of metal-on-metal hip implants.  That study appears in the June edition of Journal of Bone and Joint Surgery, and is titled, understandably, “Independent predictors of revision following metal-on-metal hip resurfacing: a retrospective cohort study using National Joint Registry data.”.

While metal-on-metal hip replacements had been seen by this UK team to have “excellent medium- to long-term results with some brands in specific subgroups,” but also that there were “high failure rates and local soft-tissue reactions in others.”

In their paper, the Jameson team cited research done by the UK National Joint Registry, which had collected data on all hip replacements performed between 2003 and 2010.  Analyzing that pool of 27,971 hip resurfacings, the team found that 3.59% required revision surgery.  Interestingly, women were found to be 30% more likely than men to undergo this replacement surgery.

The team also found that certain brands were more likely than others to fail and require replacement.  Compared to the Birmingham Hip Resurfacing model (BHR), the DePuy ASR models were 2.82 times as likely to fail.  The Conserve model was 1.43 times as likely to fail, the Durom implant 1.67 times, and the Recap model 1.58 times as likely to fail than the BHR.  Clearly, the DePuy ASR model is the least reliable of these hip replacement systems.

Further, this team found that “smaller femoral head components were also significantly more likely to require revision” — those smaller than 44mm were more than twice as likely to fail as were larger ones.

In general, the best results were found with younger male patients who used the BHR.

Due to the fact that the risk for revision reported by DePuy was significantly lower than that determined by independent researchers, the DePuy ASR and DePuy ASRXL hip replacement systems were recalled in 2010 and a number of DePuy ASR lawsuits have been filed.

If you or a loved one used a DePuy ASR hip replacement and required revision surgery or suffered other DePuy complications, you may be entitled to significant financial compensation for your injury and undue risk for injury.  For a free consultation, contact our team of DePuy lawyers at the information provided below.  We have the skills, resources, and experience required to win the justice you deserve.  Call today and see how we can help!

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.

DePuy ASR metal-on-metal hip implants are frequently associated with premature device failure requiring revision (this prompted the recall of the ASR/ASRXL models in 2010) and femoral fracture.  Much of the more recent research deals with the ASR complication of metal dissemination – the wearing off of tiny metal particles from the implants that enter the blood and cause a variety of complications such as kidney and liver damage, severe skin irritation, pseudotumors, and increased cancer mortality, but other articles demonstrating ASR risks are also currently being published.

In a 2013 edition of Clinical Orthopaedics and Related Research, DC Huang et al. focused their research on revision rates for several commonly-used metal-on-metal hip replacement systems, and found that “The recalled DePuy ASR™ implant was six times as likely to be revised as other MOM THAs.” (For clarity, MOM stands for metal-on-metal, and THA stands for total hip arthroplasty, or total hip replacement.)

Due to the fact that many people have entered into hip replacement surgery using DePuy ASR hip implants unaware of the revision (replacement) rate associated with the ASR, a number of DePuy ASR lawsuits are currently being filed.  If you or a loved one used a DePuy ASR hip replacement and you suffered premature device failure or another ASR complication, you may be entitled to significant financial compensation for your injury: it is becoming abundantly clear that DePuy knew (or should have known) of the high revision rates associated with their products but failed to act.

For a free, no-obligation case consultation, contact our team of DePuy ASR lawyers at the information provided below.  We have the skills, resources, and experience required to win the justice you deserve.  Call today and see how we can help!

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.

Here is an excerpt from the abstract of a 2013 article published in Clinical Orthopaedics and Related Research by KT Hug et al.: “The Articular Surface Replacement™ (ASR™) metal-on-metal hip arthroplasty system (DePuy Orthopaedics, Inc, Warsaw, IN, USA) reportedly has a higher than anticipated early failure rate leading to a voluntary recall. This prompted us to evaluate all ASR™ components implanted at our center.” (hyperlink added)

This team “reviewed all 172 patients (190 hips) who underwent THA (149 hips) or hip resurfacing (41 hips) with the ASR™ system”, determined the rates of failure for the hips, and determined blood metal ion levels from 93 patients at their most recent follow-up appointment.  The Hug et al. team evaluated blood metal ion levels because recent research has shown that tiny pieces of metal debris can wear off the DePuy ASR and other metal-on-metal hip replacements, enter the bloodstream, and cause a variety of problems ranging from kidney and liver damage to severe skin irritation and cancer.

Of the 190 hip replacements performed by this center, 24 – 13% – had required replacement surgery.  This is dramatically higher than the figures DePuy reported, which estimated about 1-2% of hip implants would fail and require replacement.

Interestingly, this team proposed in its conclusion that “ Blood metal ion levels and MRI can be used to evaluate patients with underperforming implants”, suggesting that hips that are at risk of failure may disseminate more metal ions into the blood prior to doing so, thus allowing doctors and patients a warning signal.

Due to the fact that research such as this demonstrates rates of DePuy hip replacement failure significantly higher than that reported by the manufacturer, a number of DePuy ASR lawsuits are currently being filed.

If you or a loved one used a DePuy ASR hip replacement and suffered premature device failure or another ASR complication, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of DePuy ASR lawyers at the information provided below.  We have the compassion, resources, and skills required to win the justice you deserve.

Call today and see how we can help!

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.

In 2012, GS Whitwell et al. published a report in the medical journal Hip International titled “The articular surface replacement implant recall: a United Kingdom district hospital experience.” summarizing the experience of one hospital after the 2010 DePuy ASR recall.

At the time of the ASR recall in 2010, 111 of 121 recently implanted DePuy hips were surviving, suggesting a revision rate of 8%.  Shortly after the recall, another seven hips “were listed for revision and a further 9 were kept under close surveillance,” making the revision rate just above 13%.

“One year after completion of the recall process 23 hips (19 ASR/XL and 4 RHA’s) had been revised” and sadly, “A diagnosis of adverse reaction to metal debris (ARMD) was made at surgery in all but two hips.”

The team further writes that “Our current revision rate for ASR RHA is 19% (mean follow-up 62 months, range 29-80) and for the ASR/XL is 19% (mean follow-up 53 months, range 10-80)” and places the 5-year survival rate of the DePuy ASR hip replacements at just over 80%.  Whitwell et al. warn that “Given experience elsewhere we expect this rate may increase significantly with time.”

Due to the fact that many papers similar to this have been published, demonstrating that DePuy knew, or should have known, the real revision rates for its products, a number of DePuy ASR lawsuits have been filed.  If you or a loved one used a DePuy ASR and suffered premature device failure, elevated blood metal ion levels, or another ASR complication, you may be entitled to significant financial compensation.

For a free, no-obligation case consultation, contact our team of DePuy ASR lawyers at the information provided below.  We have the skills, resources, and experience required to win the justice you deserve.  Call today and see how we can help.

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.

In 2013, a medical research team led by F. Randelli published an article in which it is stated “Patients with ASR implants (resurfacing and large-diameter (XL) metal-on-metal (MoM) total hip arthroplasty), even if asymptomatic and with a stable prosthesis, may present extremely high blood metal ion levels.”  This article was titled “Radiographically undetectable periprosthetic osteolysis with ASR implants: the implication of blood metal ions.” and appears in the September 2013 edition of The Journal of Arthroplasty.

For clarity, “ASR implants” refers to two different kinds of metal-on-metal hip replacement systems offered by DePuy Orthopaedics, Inc., both of which were recalled in 2010.  These are the ASR (Articulated Surface Replacement), used in hip resurfacing procedures, and the ASRXL, used in total hip arthroplasty.

This research team studied 14 ASR revision (implant replacement) procedures, “focusing on osteolysis and their radiographic correspondence and their correlation with blood metal ion levels.” (hyperlink added)

“At revision, seven hips revealed severe periacetabular osteolysis which was radiographically undetectable in six and asymptomatic in five. Seven hips with no acetabular osteolysis had significantly lower serum Cr and Co ion concentrations (respectively 25.2, 41.1 μg/l) compared to the seven hips with severe acetabular bone loss (respectively 70.1, 147.0 μg/l).”

As such, the team concluded “Elevated blood metal ion levels should be considered as a warning of undetectable and ongoing periprosthetic osteolysis in asymptomatic patients with ASR prosthesis.”

If you or a loved one used DePuy ASR hip replacement and suffered osteolysis, elevated blood metal ion levels, femoral fracture, premature device failure, or another ASR complication, you may be entitled to significant financial compensation through a DePuy ASR lawsuit.  The problem is that DePuy grossly underestimated the risk rates for these complications, and as a result, many people entered into ASR replacement procedures unaware of the risks they faced.

For a free, no-obligation case consultation, contact our team of DePuy ASR lawyers at the information provided below.  We have the compassion, resources, and experience required to win the justice you deserve.

Call today and see how we can help!

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.

In 2013, a team of researchers led by A. Reito published a paper in Clinical Orthopaedics and Related Research titled “High prevalence of adverse reactions to metal debris in small-headed ASR™ hips.” with two ideas in mind.  First, these researchers note that “There has been increasing concern of metal-on-metal (MOM) hip replacements regarding adverse reactions to metal debris” and second, sadly, “Information regarding prevalence and risk factors for these adverse reactions is scarce.” (hyperlink added)

As such, this study had two goals.  First, these researchers aimed to determine “the prevalence of adverse reactions to metal debris among patients who received small-headed (< 50 mm) Articular Surface Replacement (ASR™) prostheses in hip resurfacing procedures or the ASR™ XL prostheses during THAs at our institution” (the Coxa Hospital for Joint Replacements) and second, to determine “the risk factors for adverse reactions to metal debris and if they are different in hip resurfacing replacements compared with THAs”.

For clarity, a THA is a total hip arthroplasty, or hip replacement.

Of 482 hip replacements, this research team found that at follow-up, “62 hips (34%) have been revised.”  It is important to note first that this rate for revision surgery is about 15 times higher than the estimated revision rate for ASR hips reported by DePuy, the manufacturer of the ASR/ASRXL models, which stated that at 5 years only about 1-2% would require revision (replacement) surgery.

Researchers write that “The majority (85%) were revised owing to causes related to adverse reactions to metal debris. The 7-year survivorship was 51% for the ASR™ hip replacement cohort and 38% for the ASR™ XL THA cohort, respectively” and found that “Reduced cup coverage was an independent risk factor for adverse reactions to metal debris in both cohorts.”

Accordingly, the Reito team concluded that “Adverse reactions to metal debris are common with small-headed ASR™ prostheses. Risk factors for these adverse reactions differ between hip resurfacing procedures and THAs.” and that “Our results suggest a more complicated failure mechanism in THAs than in hip resurfacing procedures.”

Due to the fact that many patients received DePuy ASR hip replacement implants unaware of the high risk for failure and adverse reactions to metal debris associated with these products, a number of DePuy ASR lawsuits have been filed.  If you or a loved one used a DePuy ASR hip implant and suffered one of these or another DePuy ASR side effect, you may be entitled to significant financial compensation for your injuries.

For a free, no-obligation case consultation, contact our team of DePuy ASR lawyers at the information provided below.  We have the compassion, resources, and experience required to win the justice you deserve.

Call today and see how we can help!

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.

Published online in June 2013 (print Jan. 2014) in The Journal of Arthroplasty, a study titled “The Effect of Acetabular Inclination on Metal Ion Levels Following Metal-on-Metal Hip Arthroplasty.” aimed to determine the degree to which the specific positioning of DePuy ASR hip replacement components changed blood metal ion levels in hip replacement patients.

While all DePuy ASR hip replacement systems are associated with metal dissemination – the wearing off of tiny metal particles into the blood (something that may lead to a myriad of medical conditions ranging from severe skin irritation to cancer), these researchers determined that “The correlation between inclination angle and cobalt levels was significant only with small femoral components, although it was still weak.”

Though other researchers have found that certain metal-on-metal hip replacement angles are associated with increased blood metal ion levels, due to this weak correlation, these researchers concluded that “the acetabular inclination angle is not a meaningful determinant of metal ion levels in ASR arthroplasties.”

It is important to realize that simply because this research team did not find that certain DePuy component orientations lead to more or less metal ions in the blood, this research did not conclude that the DePuy ASR doesn’t leak metal ions into the blood, the team merely found that no certain positioning was more advantageous in that regard.

Due to the fact that a number of people have used DePuy ASR metal-on-metal hip replacement systems unaware of the risk for elevated blood metal ion levels and subsequent premature device failure, a number of DePuy ASR lawsuits have been filed.

If you or a loved one used a DePuy ASR hip replacement and suffered an ASR complication or negative side effect, you may be entitled to significant financial compensation for your undue pain and suffering.  For a free, no-obligation case consultation, contact our team of DePuy ASR lawyers

at the information provided below.  We have the skills, resources, and experience required to win the justice you deserve.

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.

A 2013 article published in Hip International titled “Blood levels of cobalt and chromium are inversely correlated to head size after metal-on-metal resurfacing arthroplasty.” by a team of researchers led by MC Parry from the UK aimed to “assess the effect of head size, implant design and component positioning on metal production by resurfacing arthroplasties.”

Stating that “Resurfacing arthroplasty has fallen out of favour in recent years due to unfavourable survivorship in joint registries and alarming reports of soft tissue reactions around metal on metal prostheses”, the team “measured whole blood cobalt and chromium and component position in matched populations implanted with two designs of resurfacing arthroplasty over a two-year period.”

While “both implants resulted in a significant increase in blood metal levels”, the DePuy “ASR design generated significantly higher metal levels”.

Finding that smaller metal hip replacement components was correlated with an increase in blood metal ion levels, the team concluded that “As increased metal generation has been correlated to wear and therefore failure, caution must be used on implantation of smaller components and indeed, in those who require smaller components, alternative bearing materials should be considered.”

Because DePuy failed time and again to notify users of the risk for metallosis and elevated blood metal ion levels associated with the ASR and ASRXL metal hip replacement systems, a number of DePuy ASR lawsuits have been filed.

If you or a loved one used a DePuy ASR hip replacement system and suffered elevated blood metal ion levels as a result, contact our team of DePuy ASR lawyers at the information provided below.  You may be entitled to significant financial compensation from the manufacturer for your undue injuries.

For a free, no-obligation DePuy ASR lawsuit consultation, call or e-mail our team at your convenience.  We have the skills, resources, and experience required to win the justice you deserve.

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.

In a paper titled “Hip arthroplasty with the articular surface replacement (ASR) system: survivorship analysis and functional outcomes.” published in European Journal of Orthopaedic Surgery and Traumatology, the authors begin by stating “The articular surface replacement (ASR) hip resurfacing system, now withdrawn, has the highest all-cause revision rate (24.2 % at 7 years) compared with other resurfacing brands.”  As such, the DePuy ASR has prompted many lawsuits.

This medical research team, led by one S. Shemesh, “reviewed the medical records and examined all 55 patients (57 hips) who had THA by the senior author between March 2005 and November 2008” and “recorded the Oxford Hip scores, metal ion levels, need for revision, the indication for revision, and the intra-operative findings” for each patient.

This team found that after five years, the survival rate for the ASR implants was 85.1%; that is, 14.9% of the metal-on-metal hip replacements failed at five years – a dramatic increase in failure rate over that disclosed by DePuy.

“At the time of recall, 10 (17.5 %) of fifty-seven THAs were already revised. Four (40 %) of the ten revisions were performed within 1 month of the operation due to a periprosthetic fracture. Three other revisions were due to avascular necrosis at a mean time of 3.6 years. One patient was revised due to infection. The two remaining revisions were due to ongoing groin pain, in one of whom the cup was found to be loose.”

Due to the fact that DePuy disclosed a failure rate for its ASR/ASRXL hip replacement systems significantly lower than that reported by independent researchers, a number of DePuy ASR lawsuits have been filed.

If you or a loved one used a DePuy ASR / ASRXL hip replacement system and suffered premature ASR failure or another ASR complication, contact our team of DePuy lawyers at the information provided below.  We have the skills, resources, and experience required to win the justice you deserve.

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.

In 2013, a team of medical researchers from Uppsala University Hospital in Uppsala, Sweden led by NP Hailer published a paper titled “High Metal Ion Levels After Use of the ASR™ Device Correlate With Development of Pseudotumors and T Cell Activation.” in Clinical Orthopaedics and Related Research studying the safety of the DePuy ASR hip replacement system.

The authors state “Pseudotumors and immunologic alterations are reported in patients with elevated metal ion levels after resurfacing arthroplasty of the hip” but that “A direct association of increased cobalt and chromium concentrations with the development of pseudotumors has not been established.”

Among other things, the team hypothesized that “patients with higher blood cobalt and chromium concentrations are more likely to have pseudotumors develop” and that “elevated metal ion levels, small implant size, cup inclination angle, and patient age are risk factors for the development of pseudotumors.”

For data, the team studied 78 patients in whom 84 DePuy ASR hip replacements were implanted between 2006 and 2010.  The team found that “Cobalt and chromium concentrations were greater in patients with pseudotumors than in those without”, thus demonstrating that elevated metal ion levels from metal-on-metal hip implants are associated with pseudotumor development.

Further, the paper demonstrated that “patients with larger implants were less likely to have them develop … age and cup inclination were not risk factors.”

Due to the fact that DePuy Orthopaedics, Inc. failed time and again to notify users of these risks, a number of DePuy ASR lawsuits have been filed.  If you or a loved one used a DePuy ASR hip replacement and suffered premature device failure, femoral fracture, elevated blood metal ion levels, or another DePuy ASR complication, you may be entitled to significant financial compensation.

For a free, no-obligation case consultation, contact our team of DePuy ASR lawyers at the information provided below.  We have the skills, resources, and experience required to win the justice you deserve.

Call today and see how we can help!

(855)  452 – 5529

justinian@dangerousdrugs.us

Our DePuy ASR™ / ASR™ XL Hip Replacement Lawsuit Information page is a great place to start if you have any questions about DePuy ASR metal-on-metal hip replacements.